Institutional Biosafety Committee (IBC)
Office of Regulatory Affairs (ORA)

# INSTITUTIONAL BIOSAFETY COMMITTEE
# IBC MEETING MINUTES
## January 8, 2026

**MEMBERS PRESENT:** JoEllyn McMillan - Chair, Pete Iwen – Vice Chair, Eric Bradley, Paul Denton, Ryan Duden, Jared Evans, Noel Johnson, Jim Kee, Mimi McCann, Jenna McKenzie, and Rick Starlin

**NON-VOTING ALTERNATE MEMBERS PRESENT:** Mackenzie Conrin and Makayla Walker

**ADMINISTRATIVE STAFF PRESENT**: Jackie Hollinger and Deron Anderson

**GUESTS PRESENT:** Desmond Amponsah

Dr. McMillan opened the meeting at 2:31pm.

### A. Review and Acceptance of IBC Minutes

The IBC voted (11 in favor, 0 against, 0 abstention) to accept December 11, 2025 minutes.

### B. Information, Education and Policy Items

### C. Special Notification/Review

none

### D. Incident and Event Reports Special Notification and/or Review Approved

none

### E. IBC Initial Research Proposals and/or Previously Tabled

1) **IBC#:** 25-12-025-ABL2
**PI:** Ahodantin, James
**Title:** HBV and Liver Disease
**Biohazardous Agents:** Adeno-associated virus, Hepatitis B
**Applicable NIH Guidelines:** III-D-4
**Summary:** In this protocol an animal model for HBV infection will be established using an AAV-HBV expression system. Immune-related responses in mice will be assessed in the context of administration of the HEPLISAV-B vaccine and/or immune system modulation therapies.
**Committee Recommendation:** In Section II, also select practices for Risk Group 2 agents. Add mouse cells/tissues. If tissues from HBV+ animals will be harvested and manipulated, describe this in the description of work. Specify which product numbers are available and

which will be used in Section II.2.B. Provide IACUC protocol numbers in Section III.2. In Section III.2, state that personnel performing injections will also wear face and eye protection.
**Training:** Training is completed and up-to-date.
**Motion:** Conditionally Approved
**Vote Counts: 11-0-0**

## F. IBC Change in Protocol

2) **IBC#:** 18-01-001-ABL2
**PI:** Xie, Jingwei
**Title:** Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing for Tissue Regeneration
**Biohazardous Agents:** *Acinetobacter baumannii*, *Bacillus subtilis*, *Escherichia coli* K-12, Human cell line/cells/tissues, *Klebsiella pneumoniae*, Murine cell line, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, methicillin-resistant, Lentiviral Vector, Plasmid
**Applicable NIH Guidelines:** III-D-4-b
**Summary:** This change is proposed to evaluate the activity of the new investigational agent against clinically relevant resistant strains. Since vancomycin-nonsusceptible *S. aureus* represents an important emerging pathogen with significant therapeutic challenges, including this strain will provide a more comprehensive assessment of antimicrobial performance under clinically relevant conditions.
**Committee Recommendation:** Address all comments from pre-review. In Section II.1, provide the strain and brief description of work for *S. aureus*, vancomycin nonsuseptible.
**Training:** Training is completed and up-to-date.
**Motion:** Conditionally Approved
**Vote Counts: 11-0-0**

## G. IBC Continuing Review Active Research

3) **IBC#:** 08-05-011-ABL2
**PI:** Kielian, Tammy
**Title:** The role of *S. aureus* in disease pathogenesis
**Biohazardous Agents:** Human cell line/cells/tissues, *Staphylococcal enterotoxins* A,B,C,D,E subtypes,(less than 100 mg) *Staphylococcus aureus* (not vancomycin-resistant), *Staphylococcus aureus*, methicillin-resistant
**Applicable NIH Guidelines:** Exempt
**Summary:** This study utilizes various isolates of *S. aureus* as well as *S. aureus* a-toxin and enterotoxins to study host immune response in mouse models and using human tissue samples.
**Committee Recommendation:** Modify the language in Section II.2.B to update the personnel mentioned as they are no longer at the University. In Section II.2.C.1a, update the broken link mentioned. In Section III, update the IACUC numbers. In Section III.3, ensure that all specific strain designations of animals are provided.
**Training:** Training is completed and up-to-date.
**Motion:** Conditionally Approved

**Vote Counts: 11-0-0**

4) **IBC#:** 24-11-038-ABL2
**PI:** Hingorani, Sunil
**Title:** Research with Biological Materials in Pancreas Cancer
**Biohazardous Agents:** Murine cell line, murine primary cells, primary human cell line, lentiviral vector, plasmid, siRNA, siRNA small interfering
**Applicable NIH Guidelines:** III-D-1-a, III-D-4-b
**Summary:** This protocol will use mouse models of human pancreatic cancer to develop methods for early detection, investigate mechanisms of disease and evaluate chemopreventive and therapeutic strategies for the disease
**Committee Recommendation:** The only recommendation is to update personnel from the IACUC protocol.
**Training:** One more personnel needs to complete Biosafety Training.
**Motion:** Approved
**Vote Counts: 11-0-0**

5) **IBC#:** 18-07-015-BL2
**PI:** Korade, Zeljka
**Title:** Cholesterol Biosynthesis
**Biohazardous Agents:** *Escherichia coli* K-12, human cell line/cells/tissues, murine cell line, vesicular stomatitis virus, plasmid, shRNA short hairpin
**Applicable NIH Guidelines:** exempt
**Summary:** This protocol describes studies to examine cholesterol metabolism in the context of genetically-related syndromes of compromised cholesterol biosynthesis. Human serum samples and mouse and human cell cultures will be used in the studies. Silencing of specific genes related to cholesterol metabolism will be done using shRNA in mouse and human cell lines.
**Committee Recommendation:** Schedule a laboratory inspection
**Training:** Training is complete and up-to-date.
**Motion:** Approved
**Vote Counts: 11-0-0**

6) **IBC#:** 24-11-042-ABL2
**PI:** Korshoj, Lee
**Title:** Mechanisms influencing *Staphylococcus aureus* infection severity and persistence
**Biohazardous Agents:** *Staphylococcus aureus*, methicillin-resistant, *Staphylococcus enterotoxin* (less than 100mg)
**Applicable NIH Guidelines:** III-D-4
**Summary:** The mechanisms influencing *Staphylococcus aureus* infection severity and persistence are explored through a variety of in vitro and in vivo experiments
**Committee Recommendation:** No comments to send, move reviews to a 3-year cycle.
**Training:** All training is complete and up-to-date.
**Motion:** Approved
**Vote Counts: 11-0-0**

7) **IBC#:** 23-12-033-BL2
**PI:** D'Angelo, Christopher

**Title:** A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel [redacted] in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
**Biohazardous Agents:** Human cell line/cells/tissues, lentiviral vector
**Applicable NIH Guidelines:** III-C-1
**Summary:** This is a clinical trial to determine a safe/tolerable dose of various adjunctive therapies in conjunction with CAR-T cell therapy for treatment of myeloma. The CAR-T cells are engineered to express a certain specific chimeric antigen receptor using a lentiviral vector system. Patients PBMCs are collected and cell engineering is done off-site.
**Committee Recommendation:** none
**Training:** All training is complete and up-to-date
**Motion:**
**Vote Counts: 11-0-0**

There being no further business, Dr. McMillan adjourned the meeting at 2:55pm

Respectfully Submitted,

[redacted]

JoEllyn McMillan, PhD
Chair, IBC
JM

**ADDENDUM**
**January 8, 2026**
**IBC REVIEW LETTER/EMAIL TO INVESTIGATORS**

| IBC # | Date of Letter/Email |
|---|---|
| 25-12-025-Pending | 01/09/2026 |
| 18-01-001-ABL2 | 01/09/2026 |
| 08-05-011-ABL2 | 01/09/2026 |
| 24-11-038-ABL2 | 01/09/2026 |
| 18-07-015-BL2 | 01/09/2026 |
| 24-11-042-ABL2 | 01/09/2026 |
| 23-12-033-BL2 | 01/09/2026 |